Kristian B Filion1,2,3, Maria Eberg1, Pierre Ernst1,2. 1. Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. 2. Department of Medicine, McGill University, Montreal, Quebec, Canada. 3. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada.
Abstract
PURPOSE: The potential consequences of confounding due to drug formulary restrictions in pharmacoepidemiologic research remain incompletely understood. Our objective was to illustrate this potential bias using the example of fluticasone/salmeterol combination therapy, an oral inhaler used to treat asthma and chronic obstructive pulmonary disease, whose use is restricted in the province of Quebec, Canada. METHODS: We identified all new users of fluticasone/salmeterol in Quebec's administrative databases and classified those who received their initial dispensing of fluticasone/salmeterol between 1 September 1999 and 30 September 2003 as users from the liberal period and those who received it between 1 January 2004 and 31 October 2006 as users from the restricted period. The primary outcome was time to first hospitalization for respiratory causes within 12 months of cohort entry. RESULTS: Our cohort included 72 154 new users from the liberal period and 5058 from the restricted period. Compared with use during the liberal period, use during the restricted period was associated with an increased rate of hospitalization for respiratory causes (crude hazard ratio [HR] = 1.41, 95% confidence interval [CI] = 1.32, 1.51). Subsequent adjustment for age, sex, and hospitalization for respiratory causes in the previous year attenuated the association (HR = 1.05, 95%CI = 0.98, 1.12). Further adjustment for other potential confounders resulted in a lower rate during the restricted period (HR = 0.78, 95%CI = 0.73, 0.83). CONCLUSIONS: Formulary restrictions can result in substantial and unexpected confounding and should be considered during the design and analysis of pharmacoepidemiologic studies.
PURPOSE: The potential consequences of confounding due to drug formulary restrictions in pharmacoepidemiologic research remain incompletely understood. Our objective was to illustrate this potential bias using the example of fluticasone/salmeterol combination therapy, an oral inhaler used to treat asthma and chronic obstructive pulmonary disease, whose use is restricted in the province of Quebec, Canada. METHODS: We identified all new users of fluticasone/salmeterol in Quebec's administrative databases and classified those who received their initial dispensing of fluticasone/salmeterol between 1 September 1999 and 30 September 2003 as users from the liberal period and those who received it between 1 January 2004 and 31 October 2006 as users from the restricted period. The primary outcome was time to first hospitalization for respiratory causes within 12 months of cohort entry. RESULTS: Our cohort included 72 154 new users from the liberal period and 5058 from the restricted period. Compared with use during the liberal period, use during the restricted period was associated with an increased rate of hospitalization for respiratory causes (crude hazard ratio [HR] = 1.41, 95% confidence interval [CI] = 1.32, 1.51). Subsequent adjustment for age, sex, and hospitalization for respiratory causes in the previous year attenuated the association (HR = 1.05, 95%CI = 0.98, 1.12). Further adjustment for other potential confounders resulted in a lower rate during the restricted period (HR = 0.78, 95%CI = 0.73, 0.83). CONCLUSIONS: Formulary restrictions can result in substantial and unexpected confounding and should be considered during the design and analysis of pharmacoepidemiologic studies.
Authors: Krista F Huybrechts; M Alan Brookhart; Kenneth J Rothman; Rebecca A Silliman; Tobias Gerhard; Stephen Crystal; Sebastian Schneeweiss Journal: Am J Epidemiol Date: 2011-09-20 Impact factor: 4.897
Authors: Olaf H Klungel; Edwin P Martens; Bruce M Psaty; Diederik E Grobbee; Sean D Sullivan; Bruno H Ch Stricker; Hubert G M Leufkens; A de Boer Journal: J Clin Epidemiol Date: 2004-12 Impact factor: 6.437
Authors: Kristian B Filion; Dan Chateau; Laura E Targownik; Andrea Gershon; Madeleine Durand; Hala Tamim; Gary F Teare; Pietro Ravani; Pierre Ernst; Colin R Dormuth Journal: Gut Date: 2013-07-15 Impact factor: 23.059
Authors: Sinéad M Langan; Sigrún A J Schmidt; Kevin Wing; Vera Ehrenstein; Stuart G Nicholls; Kristian B Filion; Olaf Klungel; Irene Petersen; Henrik T Sørensen; William G Dixon; Astrid Guttmann; Katie Harron; Lars G Hemkens; David Moher; Sebastian Schneeweiss; Liam Smeeth; Miriam Sturkenboom; Erik von Elm; Shirley V Wang; Eric I Benchimol Journal: CMAJ Date: 2019-06-24 Impact factor: 8.262
Authors: Sinéad M Langan; Sigrún Aj Schmidt; Kevin Wing; Vera Ehrenstein; Stuart G Nicholls; Kristian B Filion; Olaf Klungel; Irene Petersen; Henrik T Sorensen; William G Dixon; Astrid Guttmann; Katie Harron; Lars G Hemkens; David Moher; Sebastian Schneeweiss; Liam Smeeth; Miriam Sturkenboom; Erik von Elm; Shirley V Wang; Eric I Benchimol Journal: BMJ Date: 2018-11-14
Authors: Vanessa C Brunetti; Audray St-Jean; Sophie Dell'Aniello; Anat Fisher; Oriana H Y Yu; Shawn C Bugden; Jean-Marc Daigle; Nianping Hu; Silvia Alessi-Severini; Baiju R Shah; Paul E Ronksley; Lisa M Lix; Pierre Ernst; Kristian B Filion Journal: BMC Endocr Disord Date: 2022-09-29 Impact factor: 3.263